industrial perspective on deep brain stimulation: history, current state and future developments
Clicks: 282
ID: 203370
2011
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
282 views
44 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #48 of 89 articles by views in drug research
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Deep Brain Stimulation (DBS) emerged in the late 1960’s as a possible therapeutic alternative tolesioning in patients with severe, chronic, intractable pain. DBS devices in the era were based oncardiac pacing technology but were greatly modified in implementation due to the unique needs ofDBS. Clinical studies in the 1970’s and early 1980’s revealed a technique with modest resultswhich did not lead to regulatory approval for the treatment of pain. In the 1980’s a new application for DBS emerged in the treatment of movement disorders. Clinical trials confirmed the robustness of the therapy leading to approvals by regulatory authorities in the US and Europe for the treatment of tremor and the symptoms of Parkinson’s disease. Technology based on that used for earlier clinical research in pain was improved by leveraging advances in cardiac pacing technology resulting in the sophisticated and reliable systems available today. In the 1990’s scientific exploration began in the treatment of psychiatric disorders which is ongoing today. Simultaneously, studies into the treatment of epilepsy were begun which resulted in regulatory approval in Europe. Suggestions have been made to expand these scientific explorations to other central nervous system dysfunctions. Opportunity remains to improve the technology including individualized and symptom specific stimulation patterns, more physician and patient friendly programming and possibly closed loop systems for more situation dependent and effective therapy.
| Reference Key |
esarem-aslani2011frontiersindustrial
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Ali eSarem-Aslani;Keith eMullett |
| Journal | drug research |
| Year | 2011 |
| DOI |
10.3389/fnint.2011.00046
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.